Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2019

Open Access 01-12-2019 | Nephrostomy | Research

Malignant ureteral obstruction: experience and comparative analysis of metallic versus ordinary polymer ureteral stents

Authors: Yue Chen, Cheng-yi Liu, Zhi-hong Zhang, Peng-cheng Xu, De-gang Chen, Xin-huan Fan, Ji-ci Ma, Yi-peng Xu

Published in: World Journal of Surgical Oncology | Issue 1/2019

Login to get access

Abstract

Background

To study the outcome and experience of using metallic stents in treating patients with malignant ureteral obstruction (MUO).

Methods

Seventy-six patients with MUO were assigned to the metallic stent group (MSG) or the ordinary polymer stent group (OPSG) according to the different materials. The success rate of the operation, duration of operation, patency rate serum creatinine values ,postoperative complications and QOL scores were compared between the two groups.

Results

In the OPSG and MSG, the success rates of the operation were 95.5% and 96.9%, respectively, and the durations of the operation were 20.6 ± 2.2 min and 50.9 ± 10.3 min (P < 0.01), respectively. There was no significant difference between the groups in serum creatinine values at 3 days after the operation (P > 0.05); however, the creatinine values at 3 days after the operation decreased significantly compared with those before the operation (P < 0.01). In the OPSG, there was no significant difference in creatinine values between 3 days and 6 months after operation, while the creatinine values 1 year after operation were increased significantly compared to those at 3 days after the operation (P < 0.05). In the MSG, there was no significant difference among creatinine values at different intervals (P > 0.05). The total rate of post-procedural complication was lower in the MSG than that in the OPSG(P < 0.05). There was no significant difference in the QOL score between the two groups before the operation (P > 0.05); however, the QOL scores at 6 months and 1 year after the operation were higher in the MSG than that in the OPSG(P < 0.05). In the MSG, there was no significant difference in the QOL score between preoperation and 6 months after surgery. Similarly, there was also no difference in the QOL score between 6 months after surgery and 1 year after surgery(P > 0.05). On the contrary, the differences of QOL score in the OPSG group were much significant between disparate time intervals (P < 0.05).

Conclusions

For patients with MUO who require long-term retention of the stent, metallic stents with longer indwelling time are superior to ordinary polymeric stents.
Literature
1.
go back to reference Ishioka J, Kageyama Y, Inoue M, Higashi Y, Kihara K. Prognostic model for predicting survival after palliative urinary diversion for ureteral obstruction: analysis of 140 cases. J Urol. 2008;180:618–21.CrossRef Ishioka J, Kageyama Y, Inoue M, Higashi Y, Kihara K. Prognostic model for predicting survival after palliative urinary diversion for ureteral obstruction: analysis of 140 cases. J Urol. 2008;180:618–21.CrossRef
2.
go back to reference Chitale SV, Scott-Barrett S, Ho ETS, Burgess NA. The management of ureteric obstruction secondary to malignant pelvic disease. Clin Radiol. 2002;57(12):1118–21.CrossRef Chitale SV, Scott-Barrett S, Ho ETS, Burgess NA. The management of ureteric obstruction secondary to malignant pelvic disease. Clin Radiol. 2002;57(12):1118–21.CrossRef
3.
go back to reference Aravantinos E, Anagnostou T, Karatzas AD, Papakonstantinou W, Samarinas M, Melekos MD. Percutaneous nephrostomy in patients with tumors of advanced stage: treatment dilemmas and impact on clinical course and quality of life. J Endourol. 2007;21(11):1297.CrossRef Aravantinos E, Anagnostou T, Karatzas AD, Papakonstantinou W, Samarinas M, Melekos MD. Percutaneous nephrostomy in patients with tumors of advanced stage: treatment dilemmas and impact on clinical course and quality of life. J Endourol. 2007;21(11):1297.CrossRef
4.
go back to reference Mosayyebi A, Manes C, Carugo D, Somani BK. Advances in ureteral stent design and materials. Curr Urol Rep. 2018;19:35.CrossRef Mosayyebi A, Manes C, Carugo D, Somani BK. Advances in ureteral stent design and materials. Curr Urol Rep. 2018;19:35.CrossRef
5.
go back to reference Gorman SP, Jones DS, Bonner MC, Akay M, Keane PF. Mechanical performance of polyurethane ureteral stents in vitro and ex vivo. Biomaterials. 1997;18(20):1379–83.CrossRef Gorman SP, Jones DS, Bonner MC, Akay M, Keane PF. Mechanical performance of polyurethane ureteral stents in vitro and ex vivo. Biomaterials. 1997;18(20):1379–83.CrossRef
6.
go back to reference Woo KJ, Bumsik H, Hoon SJ, et al. A prospective randomized comparison of a covered metallic ureteral stent and a double-J stent for malignant ureteral obstruction. Korean J Radiol. 2018;19(4):606–12.CrossRef Woo KJ, Bumsik H, Hoon SJ, et al. A prospective randomized comparison of a covered metallic ureteral stent and a double-J stent for malignant ureteral obstruction. Korean J Radiol. 2018;19(4):606–12.CrossRef
7.
go back to reference Chow PM, Chiang IN, Chen CY, et al. Malignant ureteral obstruction: functional duration of metallic versus polymeric ureteral stents. PloS One. 2015;10(8):e0135566.CrossRef Chow PM, Chiang IN, Chen CY, et al. Malignant ureteral obstruction: functional duration of metallic versus polymeric ureteral stents. PloS One. 2015;10(8):e0135566.CrossRef
8.
go back to reference Kadlec AO, Ellimoottil CS, Greco KA, Turk TM. Five-year experience with metallic stents for chronic ureteral obstruction. J Urol. 2013;190(3):937–41.CrossRef Kadlec AO, Ellimoottil CS, Greco KA, Turk TM. Five-year experience with metallic stents for chronic ureteral obstruction. J Urol. 2013;190(3):937–41.CrossRef
9.
go back to reference Goldsmith ZG, Wang AJ, Bañez LL, Lipkin ME, Ferrandino MN, Preminger GM, Inman BA. Outcomes of metallic stents for malignant ureteral obstruction. J Urol. 2012;188(3):851–5.CrossRef Goldsmith ZG, Wang AJ, Bañez LL, Lipkin ME, Ferrandino MN, Preminger GM, Inman BA. Outcomes of metallic stents for malignant ureteral obstruction. J Urol. 2012;188(3):851–5.CrossRef
10.
go back to reference Kim M, Hong B, Park HK. Long-term outcomes of double-layered polytetrafluoroethylene membrane-covered self-expandable segmental metallic stents (Uventa) in patients with chronic ureteral obstructions: is it really safe? J Endourol. 2016;30:1339–46.CrossRef Kim M, Hong B, Park HK. Long-term outcomes of double-layered polytetrafluoroethylene membrane-covered self-expandable segmental metallic stents (Uventa) in patients with chronic ureteral obstructions: is it really safe? J Endourol. 2016;30:1339–46.CrossRef
11.
go back to reference Kim KS, Choi S, Choi YS, Bae WJ, Hong SH, Lee JY, et al. Comparison of efficacy and safety between a segmental thermo-expandable metal alloy spiral stent (Memokath 051) and a self-expandable covered metallic stent (UVENTA) in the management of ureteral obstructions. J Laparoendosc Adv Surg Tech A. 2014;24:550–5.CrossRef Kim KS, Choi S, Choi YS, Bae WJ, Hong SH, Lee JY, et al. Comparison of efficacy and safety between a segmental thermo-expandable metal alloy spiral stent (Memokath 051) and a self-expandable covered metallic stent (UVENTA) in the management of ureteral obstructions. J Laparoendosc Adv Surg Tech A. 2014;24:550–5.CrossRef
12.
go back to reference Chung HH, Kim MD, Won JY, Won JH, Cho SB, Seo TS, et al. Multicenter experience of the newly designed covered metallic ureteral stent for malignant ureteral occlusion: comparison with double J stent insertion. Cardiovasc Intervent Radiol. 2014;37:463–70.CrossRef Chung HH, Kim MD, Won JY, Won JH, Cho SB, Seo TS, et al. Multicenter experience of the newly designed covered metallic ureteral stent for malignant ureteral occlusion: comparison with double J stent insertion. Cardiovasc Intervent Radiol. 2014;37:463–70.CrossRef
13.
go back to reference Kim KH, Cho KS, Ham WS, Hong SJ, Han KS. Early application of permanent metallic mesh stent in substitution for temporary polymeric ureteral stent reduces unnecessary ureteral procedures in patients with malignant ureteral obstruction. Urology. 2015;86:459–64.CrossRef Kim KH, Cho KS, Ham WS, Hong SJ, Han KS. Early application of permanent metallic mesh stent in substitution for temporary polymeric ureteral stent reduces unnecessary ureteral procedures in patients with malignant ureteral obstruction. Urology. 2015;86:459–64.CrossRef
14.
go back to reference Christman MS, L’esperance JO, Choe CH, et al. Analysis of ureteral stent compression force and its role in malignant obstruction [J]. The Journal of Urology. 2009;181(1):392–6.CrossRef Christman MS, L’esperance JO, Choe CH, et al. Analysis of ureteral stent compression force and its role in malignant obstruction [J]. The Journal of Urology. 2009;181(1):392–6.CrossRef
15.
go back to reference Pedro RN, Hendlin K, Kriedberg C, Monga M. Wirebased ureteral stents: Impact on tensile strength and compression. Urology. 2007;70:1057–59CrossRef Pedro RN, Hendlin K, Kriedberg C, Monga M. Wirebased ureteral stents: Impact on tensile strength and compression. Urology. 2007;70:1057–59CrossRef
16.
go back to reference Nagele U, Kuczyk MA, Horstmann M, Hennenlotter J, Sievert KD, Schilling D, Walcher U, Stenzl A, Anastasiadis AG. Initial clinical experience with full-length metal ureteral stents for obstructive ureteral stenosis. World J Urol. 2008;26(3):257.CrossRef Nagele U, Kuczyk MA, Horstmann M, Hennenlotter J, Sievert KD, Schilling D, Walcher U, Stenzl A, Anastasiadis AG. Initial clinical experience with full-length metal ureteral stents for obstructive ureteral stenosis. World J Urol. 2008;26(3):257.CrossRef
17.
go back to reference Potretzke AM, Chang H, Kryger JV. Technique for Resonance® stent exchange in patients with extrinsic obstruction: description of a novel approach and literature review. J Pediatr Urol. 2012;8:557–9.CrossRef Potretzke AM, Chang H, Kryger JV. Technique for Resonance® stent exchange in patients with extrinsic obstruction: description of a novel approach and literature review. J Pediatr Urol. 2012;8:557–9.CrossRef
18.
go back to reference Borin JF, Melamud O, Clayman RV. Initial experience with full-length metal stent to relieve malignant ureteral obstruction. J Endourol. 2006;20:300–4.CrossRef Borin JF, Melamud O, Clayman RV. Initial experience with full-length metal stent to relieve malignant ureteral obstruction. J Endourol. 2006;20:300–4.CrossRef
19.
go back to reference Modi AP, Ritch CR, Arend D, Walsh RM, Ordonez M, Landman J, Gupta M, Knudsen BE. Multicenter experience with metallic ureteral stents for malignant and chronic benign ureteral obstruction. J Endourol. 2010;24:1189–93.CrossRef Modi AP, Ritch CR, Arend D, Walsh RM, Ordonez M, Landman J, Gupta M, Knudsen BE. Multicenter experience with metallic ureteral stents for malignant and chronic benign ureteral obstruction. J Endourol. 2010;24:1189–93.CrossRef
20.
go back to reference Asakawa J, Iguchi T, Tamada S, Ninomiya N, Kato M, Yamasaki T, Nakatani T. Outcomes of indwelling metallic stents for malignant extrinsic ureteral obstruction. Int J Urol. 2018;25(3):258–62.CrossRef Asakawa J, Iguchi T, Tamada S, Ninomiya N, Kato M, Yamasaki T, Nakatani T. Outcomes of indwelling metallic stents for malignant extrinsic ureteral obstruction. Int J Urol. 2018;25(3):258–62.CrossRef
21.
go back to reference Abbasi A, Wyre HW, Ogan K. Use of full-length metallic stents in malignant ureteral obstruction. J Endourol. 2013;27:640–5.CrossRef Abbasi A, Wyre HW, Ogan K. Use of full-length metallic stents in malignant ureteral obstruction. J Endourol. 2013;27:640–5.CrossRef
22.
go back to reference Patel C, Loughran D, Jones R, Abdulmajed M, Shergill I. The resonance® metallic ureteric stent in the treatment of chronic ureteric obstruction: a safety and efficacy analysis from a contemporary clinical series. BMC Urol. 2017;17(1):16.CrossRef Patel C, Loughran D, Jones R, Abdulmajed M, Shergill I. The resonance® metallic ureteric stent in the treatment of chronic ureteric obstruction: a safety and efficacy analysis from a contemporary clinical series. BMC Urol. 2017;17(1):16.CrossRef
23.
go back to reference Lópezhuertas HL, Polcari AJ, Acostamiranda A, Turk TM. Metallic ureteral stents: a cost-effective method of managing benign upper tract obstruction. J Endourol. 2010;24(3):483–5.CrossRef Lópezhuertas HL, Polcari AJ, Acostamiranda A, Turk TM. Metallic ureteral stents: a cost-effective method of managing benign upper tract obstruction. J Endourol. 2010;24(3):483–5.CrossRef
24.
go back to reference Taylor ER, Benson AD, Schwartz BF. Cost analysis of metallic ureteral stents with 12 months of follow-up. J Endourol. 2012;26(7):917–21.CrossRef Taylor ER, Benson AD, Schwartz BF. Cost analysis of metallic ureteral stents with 12 months of follow-up. J Endourol. 2012;26(7):917–21.CrossRef
25.
go back to reference Frederick L, Ellimoottil C, Kadlec A, Shah A, Turk T, Schwartz BF. Cost analysis of metallic stents for chronic ureteral obstruction: a multicenter study. Urol Pract. 2016;4:1. Frederick L, Ellimoottil C, Kadlec A, Shah A, Turk T, Schwartz BF. Cost analysis of metallic stents for chronic ureteral obstruction: a multicenter study. Urol Pract. 2016;4:1.
26.
go back to reference Baumgarten AS, Hakky TS, Carrion RE, Lockhart JL, Spiess PE. A single-institution experience with metallic ureteral stents: a cost-effective method of managing deficiencies in ureteral drainage. Int Braz J Urol. 2014;40(2):225–31.CrossRef Baumgarten AS, Hakky TS, Carrion RE, Lockhart JL, Spiess PE. A single-institution experience with metallic ureteral stents: a cost-effective method of managing deficiencies in ureteral drainage. Int Braz J Urol. 2014;40(2):225–31.CrossRef
Metadata
Title
Malignant ureteral obstruction: experience and comparative analysis of metallic versus ordinary polymer ureteral stents
Authors
Yue Chen
Cheng-yi Liu
Zhi-hong Zhang
Peng-cheng Xu
De-gang Chen
Xin-huan Fan
Ji-ci Ma
Yi-peng Xu
Publication date
01-12-2019
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2019
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-019-1608-6

Other articles of this Issue 1/2019

World Journal of Surgical Oncology 1/2019 Go to the issue